Latest News

A recent study conducted by scientists at Yale Cancer Center demonstrates that spatial gene signatures can significantly enhance the prediction of immunotherapy outcomes in patients with melanoma.

David Rimm, MD, PhD, Anthony N. Brady Professor of Pathology, professor, medicine, Medical Oncology, Yale School of Medicine; director, Physician Scientist Training Program, Pathology Research, director, Tissue Microarray Facility, director, Yale Pathology Tissue Services, Pathology, Yale Cancer Center, discusses the primary challenges in distinguishing between HER2-low and HER2-ultralow breast cancer using current immunohistochemistry diagnostic kits.

Natural killer cells hold promise for treating cancer. Yale researchers have found a way to overcome their main limitation.

Commenting on the research for Medscape Medical News, Maryam Lustberg, MD, associate professor, director of the Center for Breast Cancer at Smilow Cancer Hospital, and Yale Cancer Center, and chief of Breast Medical Oncology at Yale Cancer Center, in New Haven, Connecticut, said the study "builds on a body of work previously reported by others showing that neurofilament light chains as detected in the blood can be associated with early signs of neurotoxic injury."

Even the addition of immunotherapy “works less well,” said Dr. Roy Herbst, deputy director, chief of medical oncology and director of the center for thoracic cancers at Yale Cancer Center, during an interview with CURE®. “While we’ve seen some significant progress in the non-small cell [lung cancer] area, with targeted therapies and immunotherapies, in small cell [lung cancer], we haven't seen as much — the targeted therapies really don't apply,” Herbst said.

"It's important to catch cancer early through screening or alerting to some of these symptoms so that we diagnose cancer at an earlier stage, where it's more treatable and hopefully curable," Michael Cecchini, MD, a medical oncologist at Yale Cancer Center, said in a HuffPost interview.

A foundation started by Joseph Madri, MD, PhD, professor emeritus of pathology, and his wife, Lucille, funds many worthwhile causes, including a professorship at the Yale Department of Pathology.

A team led by Yale Cancer Center's Dr. Michael Cecchini wondered if giving patients with operable advanced pancreatic cancer FOLFIRINOX ahead of their surgery, as well as afterwards, would boost outcomes.

Dr. Michael Cecchini, co-director of the colorectal program at the Center for Gastrointestinal Cancers and medical oncologist at Yale Cancer Center, tells HuffPost that colon cancer patients can have very thin stools. “This tends to occur if tumors are present near the end of the colon or if they line the entire inside of the colon, which narrows whatever stool passes through,” Cecchini said this week. “When it exists, it is highly concerning.”